Stock Ratings / Health Care / LFCR / insiders

IMRX (30) EVMN (31) IFRX (54) CAMP (26) ⌘ Pro Terminal →

Lifecore Biomedical Inc. (LFCR) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$6.40 -1.84% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.37

Lifecore Biomedical Inc. (LFCR) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $242.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LFCR Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $6.40 (-1.84% 1D, market cap $242.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, LFCR ranks #174 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LFCR compare to IMRX and EVMN in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMRX (Immuneering Corporation (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LFCR?

▼

Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $0 in revenue (-100.0% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.37 (-0.52%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 0.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFCR)Realized 20D OHLCV Swing Band: ±1.9%

Deterministic 5-Pillar Attribution (59/100 Composite)

🔍 WHY LFCR SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (24% of score)

20D Institutional Volume Accumulation (±1.9% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$6.42-0.8% Next Q

Q2 (-2Q)

Grade C+$6.37+1.1% Next Q

Q3 (-1Q)

Grade C+$6.44-0.6% Next Q

Current

Grade C-$6.40+0.2% Hist 90D α

Trajectory: B- (67) → C- (59)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the LFCR Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 59/100 (C-) score, LFCR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.50) or 200D SMA ($5.49) invalidates the momentum regime and cuts Target Base ($6.43) toward Bear Floor ($5.02).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “LFCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 59%NO 41%Trade / Inspect Odds →

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

LFCR Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (LFCR)

No recent open-market Form 4 cluster sales or emergency dumps flagged on LFCR. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (LFCR Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

LFCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.76%📐 HORIZONTAL RANGE

2026-11-03O $6.52H $6.52L $6.40C $6.40VOL 1.02M

RES: $7.34SUP: $3.89SMA50: $5.50SMA200: $5.49

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LFCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LFCR Butterfly Map → + Track LFCR →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on LFCR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LFCR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for LFCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFCR)

Health Care Rank #174 of 1016 ⚔️ IMRX vs LFCR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LFCR vs. IMRX, EVMN, IFRX, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Lifecore Biomedical Inc. (LFCR) ranks #174 by composite RQD confidence (59/100, grade C-) and #549 by equity capitalization ($242.3M). Within this direct 5-issuer industry benchmark cohort, LFCR leads on earnings valuation at N/A trailing P/E, while IMRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
LFCR ACTIVE Lifecore Biomedical Inc.	C-	59/100	—	—	—	-1.84%	$242.3M	Benchmark Subject
IMRX Immuneering Corporation (Class A)	E	30/100	—	—	-35.0%	-6.84%	$242.5M	/imrx-vs-lfcr →
EVMN Evommune Inc.	E	31/100	—	—	-35.0%	-1.17%	$244.2M	/evmn-vs-lfcr →
IFRX InflaRx N.V.	D+	54/100	—	—	—	-3.21%	$244.6M	/ifrx-vs-lfcr →
CAMP CAMP4 Therapeutics Corporation	E	26/100	—	—	-35.0%	+1.54%	$248.5M	/camp-vs-lfcr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001005286

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $128.9M ) , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LFCR closed FY2025 with $232.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$232.2M	—
FY2024 (FY)	2025-05-25	$128.9M	-$38.7M	-$206.0K	-$13.6M	$255.4M	$110.5M
FY2023 (FY)	2024-05-26	$0	$12.0M	$257.0K	$257.0K	—	—

3. LFCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does LFCR compare to IMRX and EVMN in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for LFCR?

Where is LFCR trading relative to its 50-day, 200-day, and 52-week technical levels?

LFCR last traded at $6.40 (-1.84% on volume of 1,023,945 shares), positioning the stock +16.36% above its 50-day simple moving average ($5.50) and +16.58% above its 200-day simple moving average ($5.49). Across its 52-week range of $3.63 to $8.98, LFCR sits at the 51.8% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.9% ($6.28 to $6.52).

LFCR Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are LFCR insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies LFCR leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: LFCR RQD Cockpit LFCR 12M Forecast LFCR Earnings & Move LFCR Dividends & DRIP LFCR Insiders & 13F LFCR Whale Options LFCR Profit Sankey LFCR News & Why

ROARABLE RATING BRIEF • RQD 59/100 (C-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

LFCR — Lifecore Biomedical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, LFCR scores 57 out of 100 (letter grade D+, verdict "Roarable Sell — Weak Fundamentals / Trim"). The five pillars are: Fundamental Cash Engine at 11/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow at 13/20 (institutional accumulation and options positioning), Insider Conviction at 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the two that most directly reflect earnings power and insider alignment: the cash engine shows no return on invested capital and no free-cash-flow yield in the current data, and insider conviction is the lowest-scoring pillar. The balance sheet and institutional-flow pillars are comparatively stronger, suggesting the stock's survival-level financial metrics and some institutional interest are not the primary concern; the earnings base is. Upside would depend on the cash engine turning positive, which the source data does not currently show. This is an analytical framing, not personalized advice.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$17.5M	N/A
FY 2024 (filed 2025-05-25)	$128.9M	$-17.2M	$-38.7M	N/A	$-13.6M	$9.5M	$110.5M
FY 2023 (filed 2024-05-26)	$0.0M	$-8.8M	$12.0M	N/A	$0.3M	N/A	N/A

Per the market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 6/9, and Debt/Equity is 0.5. The reported periods show revenue of $128.9M in FY 2024 alongside a net loss of $-38.7M, while FY 2025 reports $0.0M revenue. Balance-sheet posture per the sources is a cash balance of $17.5M at FY 2025 against a $110.5M debt figure reported for FY 2024.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, six items are listed, each flagged YELLOW under the "MARKET WIRE" impact label: a conference-participation announcement, a Q2 2026 earnings call transcript, a shareholder-investigation notice from Brodsky & Smith naming LFCR among several issuers, a MarketBeat short-interest update dated October 2026, a WBOC TV piece on whether shareholders are receiving fair deals, and a Yahoo Finance seasonal-returns chart. The Butterfly graph reports no proprietary signals. Risk watch items per the wire include the shareholder-investigation notice and the short-interest update; the source data does not describe the contents of these items beyond their headlines.

Open Questions

What are the revenue drivers behind FY 2024's $128.9M and why does FY 2025 report $0.0M in revenue?
What is the nature of the shareholder investigation referenced in the Brodsky & Smith notice?
What is the composition and maturity of the $110.5M debt figure, and how does it relate to the $17.5M cash balance?
What are the trailing and forward earnings and EV/EBITDA figures, which the source data leaves unavailable?
What is the institutional and insider holding data that would support the 13F and Form 4 pillar scores?

LFCR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lifecore Biomedical Inc. (LFCR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LFCR Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 18h ago

Lifecore Biomedical to Participate at Upcoming Industry Conferences

Yahoo Finance report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 21h ago

Lifecore Biomedical Q2 2026 Earnings Call Transcript

Benzinga report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Supply Chain Digital • 1d ago

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)

Supply Chain Digital report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

Lifecore Biomedical (LFCR) Short Interest & Short Float | Updated Oct 2026 $LFCR

MarketBeat report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE WBOC TV • 1d ago

Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?

WBOC TV report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Lifecore Biomedical, Inc. (LFCR) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Traders Daily • 1d ago

The Technical Signals Behind (LFCR) That Institutions Follow

Stock Traders Daily report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 7d ago

Braemar Unveils Highly Qualified Independent Board Slate for Company’s New Chapter

DALLAS, October 26, 2026--Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") today announced that its Board of Directors (the "Board") intends to nominate eight highly qualified, seasoned leaders for

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LFCR Bull vs. Bear Conversation Board — What's Your Call at $6.40?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFCR 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $7.04 (+8.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is LFCR (D+ • RQD 57/100) a Buy at $6.52?

Welcome to the LFCR (Lifecore Biomedical Inc.) Roar Pit. Current RQD Composite is 57/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.09 (-21.9%)

Spot @ $6.52

Pump the brakes on LFCR — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on LFCR, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lifecore Biomedical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $7.50 (+15.0%)

Spot @ $6.52

LFCR cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on LFCR, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.52 (52-wk range $3.63 - $8.98), any beat on forward guidance forces shorts and underweight funds to chase.